Table 3

Narcotic use of propensity score-matched cohorts by treatment group (N = 12,248).

PCDF (N = 6124)ACDF (N = 6124)OR (95% CI) P
Frequency of narcotic use
 30-day narcotic use, n (%)4208 (68.7)4338 (70.8)0.90 (0.83–0.98)0.01
 60-day narcotic use, n (%)3990 (65.2)4185 (68.3)0.79 (0.79–0.94)0.0002
 90-day narcotic use, n (%)3818 (62.3)4055 (66.2)0.84 (0.77–0.92)<0.0001
 120-day narcotic use, n (%)3674 (60.0)3943 (64.4)0.83 (0.76–0.90)<0.0001
Level of narcotic use
 30-day mean MME, mg1584.251384.641.19 (1.11–1.28)<0.0001
 60-day mean MME, mg1601.761395.591.20 (1.12–1.28)<0.0001
 90-day mean MME, mg1614.861402.071.21 (1.12–1.29)<0.0001
 120-day mean MME, mg1624.521408.091.21 (1.13–1.29)<0.0001
  • Data presented as n (%) unless otherwise indicated.

  • ACDF, anterior discectomy and fusion; CSM, cervical spondylotic myelopathy; MME, morphine milligram equivalent; PCDF, posterior decompression and fusion.